Status:
COMPLETED
Bacteriophage Effects on Pseudomonas Aeruginosa
Lead Sponsor:
University Hospital, Montpellier
Conditions:
Cystic Fibrosis
Eligibility:
All Genders
6+ years
Phase:
NA
Brief Summary
Pulmonary phage therapy to treat bacterial infections of the respiratory tract have been investigated in animals. The aim of the present study is to evaluate the efficacy of bacteriophages in infectin...
Eligibility Criteria
Inclusion
- Informed consent
- Affiliated or benefit from a disease insurance regimen
- Men and women
- Aged from at least 6 years old
- Confirmed Diagnosis of cystic fibrosis based on presence of 2 mutations of CFTR gene and/or 2 positive tests of sweat chloride and/or 2 measures of pathologic difference of nasal potential associated to cystic fibrosis clinical signs.
- Patients able to produce sputum
- Pseudomonas aeruginosa Chronic infected patients
Exclusion
- Simultaneous participation to another project on anti-infection, anti-inflammatory or modificating agents
- Subjet in exclusion period
- Law protected patient
- Realisation of sputum production is contra-indicated
Key Trial Info
Start Date :
February 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2012
Estimated Enrollment :
59 Patients enrolled
Trial Details
Trial ID
NCT01818206
Start Date
February 1 2012
End Date
April 1 2012
Last Update
September 5 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU de Montpellier - Hôpital Arnaud de Villeneuve CRCM
Montpellier, Languedoc Roussillon, France, 34295